Title:
|
cbdMD Second Quarter 2021 Earnings Call
|
Event Date:
|
Wednesday, May 12, 2021 - 4:15 PM Eastern Time
|
Event Link:
|
Webcast URLhttps://www.webcaster4.com/Webcast/Page/2206/41216 |
Webcast Replay Expiration:
|
Thursday, May 12, 2022
|
Participant Numbers:
|
Toll Free: 888-506-0062International: 973-528-0011
Entry code (not required): 233626
|
Replay Number:
|
Toll Free: 877-481-4010International: 919-882-2331Replay Passcode: 41216
|
cbdMD, INC.
|
CONDENSED CONSOLIDATED BALANCE SHEETS
|
MARCH 31, 2021 AND SEPTEMBER 30, 2020
|
(Unaudited)
| ||
March 31,
|
September 30,
| |
2021
|
2020
| |
Assets
| ||
Current assets:
| ||
Cash and cash equivalents
|
$23,711,600
|
$14,824,644
|
Accounts receivable
|
1,848,465
|
911,482
|
Accounts receivable - discontinued operations
|
22,217
|
447,134
|
Marketable securities
|
32,034
|
26,472
|
Investment other securities
|
1,000,000
|
250,000
|
Inventory
|
4,331,545
|
4,603,360
|
Inventory prepaid
|
478,629
|
288,178
|
Prepaid software
|
-
|
174,308
|
Prepaid sponsorship
|
1,777,304
|
1,203,300
|
Prepaid expenses and other current assets
|
1,544,541
|
983,374
|
Total current assets
|
34,746,335
|
23,712,252
|
Other assets:
| ||
Property and equipment, net
|
2,976,904
|
3,183,487
|
Operating lease assets
|
6,240,059
|
6,851,357
|
Deposits for facilities
|
789,583
|
790,708
|
Intangible assets, net
|
21,635,000
|
21,635,000
|
Goodwill
|
54,669,997
|
54,669,997
|
Total other assets
|
86,311,543
|
87,130,549
|
Total assets
|
$121,057,878
|
$110,842,801
|
CONDENSED CONSOLIDATED BALANCE SHEETS
|
MARCH 31, 2021 AND SEPTEMBER 30, 2020
|
(continued)
|
(Unaudited)
| ||
March 31,
|
September 30,
| |
2021
|
2020
| |
Liabilities and shareholders' equity
| ||
Current liabilities:
| ||
Accounts payable
|
$2,835,236
|
$2,850,421
|
Accrued expenses
|
1,729,594
|
2,769,920
|
Operating leases - current portion
|
1,213,891
|
1,159,098
|
Paycheck Protection Program loan, current portion
|
1,027,403
|
854,000
|
Note payable
|
57,522
|
55,639
|
Total current liabilities
|
6,863,646
|
7,689,078
|
Long term liabilities:
| ||
Long term liabilities
|
-
|
264,367
|
Note payable
|
139,215
|
-
|
Paycheck Protection Program loan
|
428,697
|
602,100
|
Operating leases - long term portion
|
5,414,751
|
6,010,208
|
Contingent liability
|
22,300,000
|
16,200,000
|
Deferred tax liability
|
27,000
|
895,000
|
Total long term liabilities
|
28,309,663
|
23,971,675
|
Total liabilities
|
35,173,309
|
31,660,753
|
cbdMD, Inc. shareholders' equity:
| ||
Preferred stock, authorized 50,000,000 shares, $0.001
| ||
par value, 2,800,000 and 500,000 shares issued and outstanding, respectively
|
2,800
|
500
|
Common stock, authorized 150,000,000 shares, $0.001
| ||
par value, 56,337,787 and 52,130,870 shares issued and outstanding, respectively
|
56,338
|
52,131
|
Additional paid in capital
|
155,780,222
|
126,517,784
|
Accumulated deficit
|
(69,954,791)
|
(47,388,367)
|
Total cbdMD, Inc. shareholders' equity
|
85,884,569
|
79,182,048
|
Total liabilities and shareholders' equity
|
$121,057,878
|
$110,842,801
|
cbdMD, INC.
|
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
|
FOR THE THREE AND SIX MONTHS ENDED MARCH 31, 2021 and 2020
|
Three Months
|
Three Months
|
Six Months
|
Six Months
| |
Ended
|
Ended
|
Ended
|
Ended
| |
March 31,
|
March 31,
|
March 31,
|
March 31,
| |
2021
|
2020
|
2021
|
2020
| |
Gross Sales
|
$12,457,386
|
$9,703,800
|
$25,520,568
|
$20,116,291
|
Allowances
|
(658,775)
|
(304,764)
|
(1,393,654)
|
(569,019)
|
Total Net Sales
|
11,798,611
|
9,399,036
|
24,126,914
|
19,547,272
|
Cost of sales
|
3,643,127
|
2,732,076
|
7,073,402
|
6,432,613
|
Gross Profit
|
8,155,484
|
6,666,960
|
17,053,512
|
13,114,659
|
Operating expenses
|
12,323,207
|
12,267,637
|
22,981,180
|
24,827,934
|
(Loss) from operations
|
(4,167,723)
|
(5,600,677)
|
(5,927,668)
|
(11,713,275)
|
Realized and Unrealized gain (loss) on marketable and other securities, including impairments
|
2,852
|
(813,152)
|
545,562
|
(875,162)
|
(Increase) decrease of contingent liability
|
(8,871,000)
|
21,261,994
|
(17,371,000)
|
38,160,000
|
Interest (expense) income
|
(10,603)
|
35,607
|
(20,990)
|
42,875
|
Income (loss) before provision for income taxes
|
(13,046,474)
|
14,883,772
|
(22,774,096)
|
25,614,438
|
Benefit for income taxes
|
536,000
|
-
|
868,000
|
2,240,300
|
Net (Loss) Income from continuing operations
|
(12,510,474)
|
14,883,772
|
(21,906,096)
|
27,854,738
|
Net (Loss) from discontinued operations, net of tax (Note 14)
|
-
|
-
|
-
|
(41,202)
|
Net (Loss) Income
|
(12,510,474)
|
14,883,772
|
(21,906,096)
|
27,813,536
|
Preferred dividends
|
560,280
|
100,016
|
660,330
|
166,750
|
Net (Loss) Income attributable to cbdMD, Inc. common shareholders
|
$(13,070,754)
|
$14,783,756
|
$(22,566,426)
|
$27,646,786
|
Net (Loss) Income per share:
| ||||
Basic earnings per share
|
(0.24)
|
0.41
|
(0.43)
|
0.76
|
Diluted earnings per share
|
(0.24)
|
0.40
|
(0.43)
|
0.74
|
Weighted average number of shares Basic:
|
53,471,607
|
36,503,005
|
52,793,872
|
36,503,005
|
Weighted average number of shares Diluted:
|
53,471,607
|
36,336,505
|
52,793,872
|
37,336,505
|
cbdMD, INC.
|
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)
|
FOR THE THREE AND SIX MONTHS ENDED DMARCH 31, 2021 AND 2020
|
(Unaudited)
|
Three Months
|
Three Months
|
Six Months
|
Six Months
| |
Ended
|
Ended
|
Ended
|
Ended
| |
March 31,
|
March 31,
|
March 31,
|
March 31,
| |
2021
|
2020
|
2021
|
2020
| |
Net (Loss) Income
|
$(12,510,474)
|
$14,883,772
|
$(21,906,096)
|
$27,813,536
|
Comprehensive (Loss) Income
|
(12,510,474)
|
14,883,772
|
(21,906,096)
|
27,813,536
|
Preferred dividends
|
(560,280)
|
(100,016)
|
(660,330)
|
(116,750)
|
Comprehensive (Loss) Income attributable to cbdMD, inc. common shareholders
|
$(13,070,754)
|
$14,783,756
|
$(22,566,426)
|
$27,696,786
|
cbdMD, INC.
|
CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS
|
FOR THE SIX MONTHS ENDED MARCH 31, 2021 AND 2020
|
(unaudited)
|
Six Months
|
Six Months
| |
Ended
|
Ended
| |
March 31,
|
March 31,
| |
2021
|
2020
| |
Cash flows from operating activities:
| ||
Net (Loss) Income
|
$(21,906,096)
|
$27,813,536
|
Adjustments to reconcile net (income) loss to net
| ||
cash used by operating activities:
| ||
Stock based compensation
|
451,527
|
972,225
|
Restricted stock expense
|
547,140
|
138,000
|
Issuance of stock / warrants for service
|
155,695
|
28,250
|
Impairment on discontinued operations asset
|
-
|
38,002
|
Depreciation and amortization
|
473,324
|
287,457
|
Other than temporary impairment other securities and other accounts receivable
|
-
|
760,000
|
Increase/(Decrease) in contingent liability
|
17,371,000
|
(38,160,000)
|
Realized and unrealized loss of Marketable and other securities
|
(5,562)
|
115,162
|
Merchant reserve settlement
|
-
|
132,657
|
Termination benefit
|
352,279
|
-
|
Non-cash lease expense
|
611,298
|
585,020
|
Changes in operating assets and liabilities:
| ||
Accounts receivable
|
(936,983)
|
763,303
|
Deposits
|
1,125
|
(22,365)
|
Merchant reserve
|
-
|
106,590
|
Inventory
|
271,815
|
(2,270,110)
|
Prepaid inventory
|
(190,451)
|
386,149
|
Prepaid expenses and other current assets
|
44,408
|
649,308
|
Accounts payable and accrued expenses
|
(1,366,373)
|
849,113
|
Operating lease liability
|
(540,664)
|
(496,834)
|
Note payable
|
-
|
175,124
|
Deferred revenue / customer deposits
|
(41,418)
|
(7,339)
|
Collection on discontinued operations accounts receivable
|
424,917
|
250,000
|
Deferred tax liability
|
(868,000)
|
(2,240,300)
|
Cash used by operating activities
|
(5,151,019)
|
(9,147,052)
|
Cash flows from investing activities:
| ||
Proceeds from sale of other investment securities
|
(750,000)
|
-
|
Purchase of property and equipment
|
(226,542)
|
(1,796,346)
|
Cash provided (used) by investing activities
|
(976,542)
|
(1,796,346)
|
Cash flows from financing activities:
| ||
Proceeds from issuance of common stock
|
-
|
16,771,756
|
Proceeds from issuance of preferred stock
|
15,798,115
|
4,421,928
|
Note payable
|
(123,268)
|
-
|
Preferred dividend distribution
|
(660,330)
|
(166,750)
|
Deferred issuance costs
|
-
|
62,197
|
Cash provided by financing activities
|
15,014,517
|
21,089,131
|
Net increase (decrease) in cash
|
8,886,956
|
10,145,733
|
Cash and cash equivalents, beginning of period
|
14,824,644
|
4,689,966
|
Cash and cash equivalents, end of period
|
$23,711,600
|
$14,835,699
|
Supplemental Disclosures of Cash Flow Information:
| ||
Six Months
|
Six Months
| |
Ended
|
Ended
| |
March 31,
|
March 31,
| |
2021
|
2020
| |
Cash Payments for:
| ||
Interest expense
|
$7,117
|
$17,097
|
Non-cash financial activities:
| ||
Issuance of Contingent earnout shares:
|
$11,271,000
|
$-
|
Warrants issued to representative
|
$254,950
|
$524,113
|
cbdMD, Inc.
| ||||
SUPPLEMENTAL FINANCIAL INFORMATION
| ||||
RECONCILIATION OF NON-GAAP ADJUSTED INCOME (LOSS) FROM OPERATIONS
|
Three Months
|
Three Months
|
Six Months
|
Six Months
| |
Ended
|
Ended
|
Ended
|
Ended
| |
March 31,
|
March 31,
|
March 31,
|
March 31,
| |
2021
|
2020
|
2021
|
2020
| |
(Unaudited)
| ||||
GAAP (loss) from operations
|
$(4,167,723)
|
$(5,600,677)
|
$(5,927,668)
|
$(11,721,275)
|
Adjustments:
| ||||
Depreciation
|
240,517
|
174,205
|
473,323
|
287,457
|
Employee and director stock compensation (1)
|
825,833
|
435,301
|
1,090,007
|
1,115,875
|
Other non-cash stock compensation for services (2)
|
33,358
|
55,479
|
69,071
|
146,548
|
Accrual for severance
|
299,610
|
-
|
703,022
|
-
|
Accrual / expenses for discretionary bonus
|
-
|
-
|
300,000
|
222,500
|
Non-GAAP adjusted (loss) from operations
|
$(2,768,405)
|
$(4,935,692)
|
$(3,292,245)
|
$(9,948,895)
|
Attachments
- Original document
- Permalink
Disclaimer
cbdMD Inc. published this content on 12 May 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 14 May 2021 17:24:14 UTC.